Eli Lilly (LLY) Stock Forecast & Price Target

Eli Lilly has demonstrated solid growth in key product segments, with cardiovascular revenues increasing by 16.1% year-over-year in Q4, driven by a strong performance in electrophysiology, which saw a remarkable 35% growth. Additionally, revenues from neuromodulation and other therapeutic areas showed an encouraging upward trend, with a 10% and 3% increase, respectively, reflecting a diverse revenue stream and resilience across their portfolio. The positive outlook is further supported by projected growth in the electrophysiology market, which is expected to expand at approximately 15% annually, positioning Lilly for continued competitive advantage and growth in the coming years.

Eli Lilly's stock outlook is negatively impacted by several fundamental factors, notably an 18% decline following a disappointing 2026 guidance and perceived weaknesses in its electrophysiology (EP) business that fell short of Q4 consensus expectations. Concerns regarding slower-than-expected uptake of certain products, as well as increased debt leading to negative financial leverage post-M&A activities, contribute to an uncertain future for revenue growth and operating leverage. Additionally, potential risks, including pricing pressures and underwhelming performance of key medications like tirzepatide and Mounjaro, could further hinder financial performance and share price stability.